WASHINGTON, DC - SEPTEMBER 30: Pfizer CEO Albert Bourla speaks shakes hands with U.S. President Donald Trump as Centers for Medicare & Medicaid Services Mehmet Oz looks on after Trump announced a deal ...

Pfizer delivered a significant earnings surprise in its third-quarter results, demonstrating the pharmaceutical giant’s resilience amid a challenging year for its stock performance. The company’s ...

Pfizer is a Buy for medium- to long-term investors, trading at a low P/E and undervalued versus peers, with strong non-COVID growth. Strategic pivots include aggressive R&D, cost-cutting, and the ...

I reaffirm my Buy rating on Pfizer due to expected promising updates on danuglipron and strong capital efficiency metrics, despite the recent stock pullback. Pfizer's management is expected to ...